Cardiovascular outcomes in hypertensive patients: Comparing single-agent therapy with combination therapy

Michael A. Weber, Stevo Julius, Sverre E. Kjeldsen, Yan Jia, Hans R. Brunner, Dion H. Zappe, Tsushung A. Hua, Gordon T. McInnes, Anthony Schork, Giuseppe Mancia, Alberto Zanchetti

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy. BACKGROUND: Drug combinations, most often including hydrochlorothiazide (HCTZ), are now recommended for routine BP management, but their effects on cardiovascular event rates have not been compared with effective monotherapy. METHODS: We conducted retrospective analyses of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) data. VALUE compared cardiovascular event rates of valsartan and amlodipine. Patients with BPs not controlled (

Original languageEnglish
Pages (from-to)2213-2222
Number of pages10
JournalJournal of Hypertension
Volume30
Issue number11
DOIs
Publication statusPublished - Nov 2012

Keywords

  • blood pressure control
  • combination therapy
  • hypertension
  • major cardiovascular events

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cardiovascular outcomes in hypertensive patients: Comparing single-agent therapy with combination therapy'. Together they form a unique fingerprint.

Cite this